Novavax Eyes Asia Expansion As Vaccines Portfolio Progresses
This article was originally published in The Pink Sheet Daily
The U.S. vaccines company Novavax is making inroads into Asia and developing markets with its influenza and RSV vaccines.
You may also be interested in...
SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S
South Korean Government To Build New Flu Vaccine Plant As Part Of Campaign For "Vaccine Independence" From Global Giants
SEOUL - To avoid a recurrence of last year's challenge to secure flu vaccines during the A/H1N1 pandemic, South Korea's government has initiated a drive to bolster the nation's independent capacity to produce these vaccines
A recently announced three-prong partnership with India's Cadila Pharmaceuticals should enable Novavax to pay off $22 million in convertible debt due in July and still have about one year's worth of operating cash, the vaccine maker's chief executive, Rahul Singhvi, said in an interview